ClinicalTrials.gg
CompletedNCT05417334Updated Jun 9, 2026

Effect of Radiofrequency in the Treatment of de Novo Dyspareunia at 4 to 12 Months Postpartum.

An interventional study of Resistive Capicitive Monopolar Radiofrequency in Dyspareunia, sponsored by Hospital Clinic of Barcelona. Completed at 1 site in Spain. Open to female participants. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Mar 2021, registered Jun 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Sex
Female
01

Study summary

This study evaluates if the application of resistive capacitive monopolar radiofrequency therapy associated with Thiele massage is effective when treating de novo dyspareunia at 4 to 12 months postpartum.

Read the detailed description

Dyspareunia is a type of genito-pelvic pain (GPP) that takes place during vaginal penetration at some point in sexual intercourse. It greatly affects quality of life as well as psychological and sexual wellbeing. A delivery with episiotomy, perineal tearing or labor dystocia using forceps or vacuum, are risk factors that contribute to the appearance of de novo dyspareunia with a prevalence of 17-45% at 6 months postpartum.

There is no evidence in the scientific literature of the effect of radiofrequency is this group of patients, however there is a clinical trial that describes the effect in scar tissue although not in the perineum. It is for all of the above that the following project is proposed, to evaluate the effect of RF in perineal healing and vaginal trigger points caused as a consequence of GPP.

The main objective of this study is to evaluate the role that radiofrequency (RF) plays in reducing the level of pain in de novo dyspareunia in postpartum women that persists from 4 to 12 months.

02

Conditions studied

  • Dyspareunia

Browse trials for

Keywords

  • dyspareunia
  • radiofrequency
  • postpartum pain
  • perineal massage
  • episiotomy
03

In context

Dyspareunia

158 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.

This study's enrollment of 80 is above the median of 63 across 126 interventional studies indexed under Dyspareunia.

Browse Dyspareunia studies →

Lead sponsor

Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 4-12 postpartum
  • de novo dyspareunia after delivery
  • obstetric injury
  • Grant

Exclusion criteria

Exclusion Criteria:

  • radiofrequency (pacemaker, active infection or pregnancy)
  • cesarean section
  • dyspareunia previous to labour
  • previous vulvo-vaginal pathology
  • patients with postpartum depression
  • patients with a pelvic region oncological history
  • patients with a history of pelvic trauma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    ON Radiofrequency treatment

    Application of the technique in the intervention group (activated resistive capacitive monopolar radiofrequency therapy): the intervention group will receive treatment with activated RF, with the electrode at a medium intensity for 20 minutes per session during a total of 5 sessions, the 3 first ones held weekly and the 2 last ones every other week.

    Device: Resistive Capicitive Monopolar Radiofrequency

  • Sham comparator
    Sham Radiofrequency treatment

    Application of the technique in the intervention group (inactive resistive capacitive monopolar radiofrequency therapy): the intervention group will receive treatment with inactive RF, with the electrode at a medium intensity for 20 minutes per session during a total of 5 sessions, the 3 first ones held weekly and the 2 last ones every other week.

    Device: Resistive Capicitive Monopolar Radiofrequency

Interventions

  • DeviceResistive Capicitive Monopolar Radiofrequency

    5 Radiofrequency sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home

06

What researchers measure

Primary outcomes

  1. Change of the baseline Level of pain during penetration and after 5 sessions

    Using the Visual Analogue Scale (VAS), where 10 is the highest level of pain possible and 0 is no pain at all.

    Time frame: Baseline and after 7 weeks

Secondary outcomes

  1. Change of the baseline Sexual function and after 5 sessions

    Using the Female Sexual Function Index (FSFI), where higher scores indicate higher degrees of sexual functioning of a total of 36 points (and lower pain).

    Time frame: Baseline and after 7 weeks

  2. Change of the baseline muscle pain points and after 5 sessions

    A physical evaluation held by the physical therapist seeking for pain points and asking the patient to score the amount of pain using the visual analogue scale (VAS) where 10 is the highest level of pain possible and 0 is no pain at all.

    Time frame: Baseline and after 7 weeks

  3. Change in Pelvic floor dysfunctions in the baseline assesment and after 5 sessions

    Using the Pelvic Floor Distress Inventory-20 questionnaire (PFDI-20), in which the higher the score the greater the perceived impact that the pelvic floor dysfunction has on the patient's life (range 0 to 300 points).

    Time frame: Baseline and after 7 weeks

  4. Change of the baseline affection on the quality of life and after 5 sessions

    Using the EuroQuality of life-5D (EQ5D),where the maximum score of 1 indicates the best health state and therefore, higher scores indicate more severe or frequent problems (range from 0 to 10)

    Time frame: Baseline and after 7 weeks

07

Study locations

1 site
  • Hospital Clinic Barcelona
    Barcelona, Barcelona 08036, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05417334
Responsible party
Carla Box (Physical Therapist, Hospital Clinic of Barcelona) — Principal investigator
First posted
Jun 14, 2022
Start date
Mar 18, 2021
Primary completion
Jun 3, 2024
Completion
Jun 21, 2024
Last update
Jun 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion